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Abstract
Background: Worldwide, a high proportion of HIV-infected individuals enter into HIV care late. Here, our objective was to
estimate the impact that late entry into HIV care has had on AIDS mortality rates in Brazil.
Methodology/Principal Findings: We analyzed data from information systems regarding HIV-infected adults who sought
treatment at public health care facilities in Brazil from 2003 to 2006. We initially estimated the prevalence of late entry into
HIV care, as well as the probability of death in the first 12 months, the percentage of the risk of death attributable to late
entry, and the number of avoidable deaths. We subsequently adjusted the annual AIDS mortality rate by excluding such
deaths. Of the 115,369 patients evaluated, 50,358 (43.6%) had entered HIV care late, and 18,002 died in the first 12 months,
representing a 16.5% probability of death in the first 12 months (95% CI: 16.3–16.7). By comparing patients who entered HIV
care late with those who gained timely access, we found that the risk ratio for death was 49.5 (95% CI: 45.1–54.2). The
percentage of the risk of death attributable to late entry was 95.5%, translating to 17,189 potentially avoidable deaths.
Averting those deaths would have lowered the 2003–2006 AIDS mortality rate by 39.5%. Including asymptomatic patients
with CD4
+ T cell counts .200 and #350 cells/mm
3 in the group who entered HIV care late increased this proportion by
1.8%.
Conclusions/Significance: In Brazil, antiretroviral drugs reduced AIDS mortality by 43%. Timely entry would reduce that rate
by a similar proportion, as well as resulting in a 45.2% increase in the effectiveness of the program for HIV care. The World
Health Organization recommendation that asymptomatic patients with CD4
+ T cell counts #350 cells/mm
3 be treated
would not have a significant impact on this scenario.
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Introduction
Late entry into HIV care is one of the principal concerns in the
fight against the AIDS epidemic [1], significantly increasing the
incidence of infection, the risk of death from AIDS (especially in the
first year of treatment), and health care system costs, as well as
reducing the effectiveness of antiretroviral drugs [2–11]. The
problemsrelatedtolateentryintoHIVcarearecompoundedbythe
fact that, worldwide, the proportion of individuals who have never
beentestedforHIVishigh—over60%intheUSA[12],Spain[13],
Italy [14], Brazil [15], and various African countries [1]. However,
cumulative experience has shown that the interventions to increase
the rates of early diagnosis of HIV infection are effective and aid in
removing known barriers to HIV testing [16–21], allowing
individuals to gain timely access to HIV care.
The criteria adopted to define late entry into HIV care have
varied from study to study [20–27]. There is, however, a relative
consensus that these criteria should express the moment at which
the lack of treatment translates to significant harm to the health of
HIV-infected individuals. The parameters used in order to define
late entry have therefore included a combination of clinical and
immunological aspects, with the aim of identifying the phases of
progression of HIV infection in which therapeutic interventions
are no longer effective. Such phases represent missed opportuni-
ties, as occurs when treatment is given to patients with CD4
+ T cell
counts #200 cells/mm
3 [20,24,26,27] or signs and symptoms of
AIDS-defining illnesses [22,23,25]. The World Health Organiza-
tion (WHO) has recently recommended that asymptomatic
patients with CD4
+ T cell counts #350 cells/mm
3 be started on
antiretroviral therapy [28], a recommendation that has added new
elements to the discussion of late entry into HIV care. This
definition translated to a considerable increase in the estimated
number of HIV-infected individuals worldwide who require
specific care and access to antiretroviral drugs.
Discussions regarding late entry into HIV care and the effects of
late entry on the health of HIV-infected individuals would gain
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to promote timely entry into HIV care have on mortality rates and
on the effectiveness of programs providing access to antiretroviral
drugs. In Brazil, such analyses could avail themselves of the
national information systems that collect data on all individuals
treated at public health care facilities [29]. These systems are
affiliated with the AIDS Brazilian Program that promotes free,
universal access to antiretroviral drugs and drugs to treat
opportunistic infections, as well as to CD4
+ T cell counting and
viral load determination [30]. From the moment patients enter
into HIV care, these systems allow the systematization of data
related to immune status, clinical status, and mortality.
The purpose of the present study was to estimate by how much
the AIDS mortality rate in Brazil would have been reduced had it
been possible to avert the deaths that occurred in the first 12
months of treatment and were attributable to late entry into HIV
care. To that end, we calculated the prevalence of late entry
criteria among HIV-infected individuals who sought treatment in
public health care facilities, the risk ratio (RR) of death in late
entry patients compared to patients with no criteria for late entry,
the percentage of the risk of death in the first 12 months
attributable to late entry into HIV care, and the number of deaths
that could have been avoided had these patients gained timely
access to treatment. We also compared the results obtained by
applying various late entry criteria.
Methods
Ethics statement
The study protocol was approved by the Research Ethics
Committee of the Sa ˜o Paulo State STD and AIDS Referral and
Training Center, located in the city of Sa ˜o Paulo, Brazil. Because
patient data were collected from the Brazilian National Ministry of
Health (NMH) national information systems and analyzed
anonymously after the systems had been cross-referenced,
informed consent was not necessary.
Study population and information sources
The present study was undertaken as part of the evaluation of
the Brazilian response to AIDS, within the context of the
commitments made by the country during the United Nations
General Assembly Special Session on HIV/AIDS [29].
The study population comprised adults ($15 years of age) living
with HIV who entered into HIV care at public health care
facilities in Brazil between 2003 and 2006. These individuals were
monitored by the national information systems in terms of the
following:
N CD4
+ T cell count and viral load (data collected via the Sistema
de Controle de Exames Laboratoriais da Rede Nacional de Contagem de
Linfo ´citos CD4
+/CD8
+ e Carga Viral—SISCEL, Laboratory Test
Control System of the Brazilian National CD4
+/CD8
+ T
Lymphocyte Count and Viral Load Network)
N AIDS diagnosis (data collected via the Brazilian National
Epidemiological Surveillance System and compiled in the
Sistema de Informac ¸a ˜o de Agravos de Notificac ¸a ˜o—SINAN, Informa-
tion System on Disease Notification)
N death (data collected via the Sistema de Informac ¸a ˜o sobre
Mortalidade—SIM, Mortality Information System)
The data that are fed into these systems are collected, on a
compulsory basis, during clinical treatment and laboratory tests.
The forms used for data collection are standardized nationwide,
and the data are electronically transferred from each health care
facility to the appropriate systems.
In Brazil,CD4
+T cell countsareperformedupon entry into HIV
care and are repeated periodically according to the clinical status.
The laboratory staff is responsible for delivering the relevant data to
the SISCEL and simultaneously issuing the test results.
Health care facilities report cases of AIDS to the SINAN when
there is laboratory evidence of HIV infection, based on three
criteria: at least one AIDS-defining illness or a CD4
+ T cell count
,350 cells/mm
3; signs and symptoms of AIDS-defining illnesses
or AIDS-related diseases; and a mention of HIV infection or
equivalent on the death certificate. When compared with the
definition adopted by the Centers for Disease Control and
Prevention, the NMH definition allows the inclusion of cases of
AIDS at earlier stages of infection [31].
Mortality data are extracted from death certificates [32]. The
conditions and causes of death are described in a specific field and
encoded in accordance with the tenth revision of the International
Classification of Diseases. In order to minimize underreporting of
AIDS cases, deaths in which the official cause of death was an
AIDS-defining illness but HIV infection is not mentioned on the
death certificate are reviewed by professional from the state or
municipal epidemiological surveillance agency.
Studies evaluating the three systems have shown high coverage
rates. The rates for the SIM are approximately 90% in terms of
the quality of the data (the rate of ill-defined causes of death being
lower than 10%) and 83% in terms of coverage (deaths registered
in the SIM in relation to the 2002 demographic estimates) [32].
For the SISCEL, the coverage rate was shown to be 82.9% in
2006, considering the proportion of laboratories that had adopted
the system and regularly reported information [29]. For the
SINAN, the estimated coverage rate was 83.6% in 2002 and
62.3% in 2004, the parameter adopted being the retrieval of cases
by means of the SISCEL and of the Sistema de Controle Logı ´stico de
Medicamentos (SICLOM, System for the Logistic Control of
Medications) [33]. For one city in northeastern Brazil, the
coverage rate was shown to be 66.9% for the 2002–2003 period
[34]. A study investigating the completeness of the information
registered in the SINAN reported a coverage rate of 90%,
excluding data related to social variables and sexual partners [35].
In order to analyze the data, we used probabilistic record
linkage, cross-referencing the information systems, a procedure
that had previously been performed by the NMH in order to
improve the epidemiological surveillance system for AIDS [33].
Duplicate records were identified by matching the patient date of
birth, the full name of the patient, and the name of the mother of
the patient. All duplicate entries were deleted.
In order to ensure that entry into HIV care had occurred
between 2003 and 2006, the date of entry was cross-referenced
with that of the first distribution of antiretroviral drugs (available in
the SICLOM) and that of the first viral load determination
(available in the SISCEL). All patients who were identified as
having entered HIV care before 2003 were considered to be
‘‘under clinical follow-up at public health care facilities’’ and were
therefore not included in the present study.
Individuals who had not undergone CD4
+ T cell counting by
the end of the sixth month of follow-up, as well as those for whom
there were discrepancies between the date of death and that of
entry into HIV care, were not included in the analysis. Figure 1
shows a flowchart for the inclusion of patients in the study.
Definition of timely and late entry into HIV care
In the present study, the deaths of individuals who presented to
public health care facilities too late to fully benefit from
Avoidable Death and Late Entry
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that timely initiation of antiretroviral therapy with appropriate
regimens guarantees HIV-infected individuals a life expectancy
close to that observed for the uninfected population [5,36].
Patients with CD4
+ cell counts #200 cells/mm
3 or AIDS-
defining illnesses at the initial examination were therefore classified
as having entered into HIV care late, as were those who died soon
after entry (within the first 20 days after diagnosis, which is the
period of the initial hospitalization). Patients without AIDS-
defining illnesses and with CD4
+ T cell counts .200 cells/mm
3 at
the initial examination were classified as having gained timely
access to HIV care.
Asymptomatic individuals with initial CD4
+ T cell counts .200
and #350 cells/mm
3 were subsequently added to the group of
individuals who entered HIV care late. Those individuals were
included in order to perform an analysis in which the most recent
WHO recommendation for antiretroviral therapy initiation was
followed [28].
The date of entry into HIV care was considered to be that on
which the first data were entered into one of the information
systems, assuming that the first clinical follow-up event to be
registered in the information systems is the CD4
+ T cell count.
The exceptions were related to individuals who presented to public
health care facilities with AIDS-defining clinical events or those
who died soon after entry into HIV care. In such cases, the date of
entry into HIV care was considered to be that of the diagnosis of
AIDS or of death. Although uncommon, the distribution of
antiretroviral drugs can occur in the first medical appointment and
therefore determine the date of entry into HIV care. Figure 1
shows the number of patients included in the present study, by the
source of the information regarding the date of entry into HIV
care.
The first CD4
+ T cell count was defined as that performed
within six months (at most) after entry into HIV care, and AIDS-
defining illnesses were included in the analysis only if diagnosed at
the time of entry into HIV care. In our analysis of AIDS mortality,
we considered only deaths occurring within the first 12 months
after entry into HIV care and limited the analysis to those in which
the death certificate listed AIDS as the underlying cause of death
or the death was classified as AIDS-related on the epidemiological
surveillance report. A study analyzing the accuracy of identifying
deaths among AIDS patients by cross-referencing the SIM (6.4
million deaths, including all causes of death) and the SINAN
reported that, between 2002 and 2005, the sensitivity, specificity,
and positive predictive value of the strategy were, respectively,
87.6%, 99.6%, and 99.2% [37]. That study identified 17,488
deaths among AIDS patients. Of those deaths, 99% were
registered in the SINAN.
Data analysis
The analysis of the data was performed in five steps:
N We estimated the prevalence of late entry into HIV care based
on the clinical and immunological profile at presentation.
N We calculated the probability of death from AIDS in the first
12 months of HIV care—for the population as a whole, for
Figure 1. Flowchart for the inclusion of adult HIV+ in the study.
doi:10.1371/journal.pone.0014585.g001
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who entered into HIV care late. We also estimated the RR of
death as a consequence of late entry into HIV care.
N For the HIV-infected population, we estimated what percent-
age of the risk of death in the first 12 months was attributable
to late entry into HIV care, as well as the number of deaths
that could have been avoided had all individuals gained timely
access to HIV care.
N We adjusted the AIDS mortality rates by excluding the
avoidable deaths.
N We performed the aforementioned procedures again, this time
considering asymptomatic individuals with CD4
+ T cell counts
.200 and #350 cells/mm
3 as having entered HIV care late.
We subsequently compared the results with those obtained
previously.
In order to estimate the probability of death from AIDS in the
first 12 months of HIV care, we used the Kaplan-Meier method.
The log-rank test was used to compare the probability of death
from AIDS in the first 12 months of HIV care for individuals who
were diagnosed early with that observed for those who were
diagnosed late. The level of significance was set at 0.05. The RR
for death in the first 12 months due to late entry into HIV care was
adopted as an effect measure and was estimated with a log-
binomial regression model, with robust variance to estimate the
95% confidence interval (CI). We chose to use this procedure
because most of the deaths occurred in the initial follow-up period.
Patients who were lost to follow-up in the first 12 months were
censored on the date of their last contact with care (last date
registered in the information systems). Loss to follow-up was
defined as the lack of any new entries into the information systems
regarding CD4
+ T cell count, viral load, diagnosis of AIDS, or the
filling of a prescription for antiretroviral drugs for a period of more
than six months. The analyses were performed with the STATA
software, version 10 (Stata Corp., College Station, TX, USA).
The percentage of the risk of death in the first 12 months that
was attributable to late entry into HIV care was calculated using
the method proposed by Kelsey et al. [38], which is summarized
by the following expression:
totR1{timelyR
totR1
X100
where totR1 is the risk of death from AIDS in the first 12 months of
HIV care in the HIV-infected population, and timelyR is the risk of
death from AIDS among individuals who gained timely access to
HIV care.
In order to analyze the impact that late entry into HIV care has
had on the annual AIDS mortality rates, we first calculated the
number of deaths that could have been avoided had all HIV-
infected adults gained timely access to HIV care. To that end, we
took the percentage of the risk of death that was attributable to late
entry into HIV care and applied it to the total number of deaths in
the first 12 months of HIV care. We then subtracted that from the
total number of deaths from AIDS (nationwide) among those aged
15 years orolderinthecorrespondingyear and calculated the AIDS
mortality rate adjusted by excluding the avoidable deaths. These
estimates were made for each of the years in the 2003–2006 period.
Results
Between 2003 and 2006, an annual average of 33,512 HIV-
infected adults entered into HIV care via public health care facilities
in Brazil, for a total of 134,049 such patients in the period as a
whole. A total of 42 individuals (0.03%) were excluded because
there were discrepancies related to the dates of diagnosis and death,
and 18,638 (13.9%) were excluded because they had not undergone
CD4
+ T cell counting by the end of the sixth month of follow-up.
Therefore, the study comprised 115,369 patients.
Among the patients analyzed, the mean and median CD4
+ T cell
counts were 378.8 cells/mm
3 and 333.0 cells/mm
3, respectively.
Of the total of patients, 32,602 (28.3%) presented with CD4
+ T cell
counts#200 cells/mm
3.Ofthese,9,870(30.3%)alsohadanAIDS-
defining illness. In addition, 3,299 patients (2.9%) presented with
CD4
+ T cell counts .200 cells/mm
3 and AIDS-related diseases,
and 14,457 (12.5%) died soon after entry into HIV care. Therefore,
late entry into HIV care was observed in 50,358 (43.6%) of the
patients. Of these 50,358 patients, 34,088 (67.7%) presented with a
more advanced form of the infection (more severe clinical and
immunological profile), characterized by a CD4
+ T cell count
#100 cells/mm
3 or death soon after entry into HIV care (Table 1).
When individual years were analyzed separately, the prevalence
of late entry into HIV care presented a slight reduction over the
course of the period studied (p,0.001), as demonstrated by a
negative variation in the overall prevalence (24.9%), which fell
from 46.5% in 2003 to 41.6% in 2006, and by a 2.4% decrease in
the proportion of patients who presented to health care facilities
with a more severe clinical and immunological profile (from 69.3%
in 2003 to 66.9% in 2006).
Loss to follow-up in the first 12 months was observed in 16,867
patients (14.6%), 14,385 (85.3%) being lost to follow-up within the
first six months of treatment. The group of patients lost to follow-
up was characterized by better clinical and immunological status,
as evidenced by a lower prevalence of clinical manifestations (5.8%
vs. 15.0%) and a higher mean CD4
+ T cell count (1.2 times
higher). Of the individuals who gained timely access to HIV care,
12,115 (18.6%) were lost to follow-up, compared with 4,752
(9.4%) of those who entered HIV care late.
A total of 18,002 deaths (15.6% of the total of patients) were
recorded in the first 12 months of HIV care, translating to a 16.5%
probability of death from AIDS in the first 12 months of HIV care
(95% CI: 16.3–16.7; Figure 2). These deaths occurred principally in
the first six months (96.3%) and presented a significant linear
decrease that was inversely proportional to the duration of
treatment. The proportion of individuals who died soon after their
entry into HIV care (80.3% in the period under study) contributed
to the fact that the deaths were concentrated in the first six months.
Even after the individuals who died soon after their entry into HIV
care had been excluded from the analysis, the proportional
mortality in the first six months of HIV care remained at 81.2%.
Nearly all of the deaths (97.5%) occurred among the individuals
who entered into HIV care late. As can be seen in Figure 3, the
probability of death in the first 12 months for these patients was
36.3% (95% CI: 35.9–36.7), compared with 1.0% (95% CI: 0.9–
1.1) for those who gained timely access to HIV care, corresponding
to a RR of 49.5 (95% CI: 45.1–54.2; Table 2). It is of note that
97.9% of the deaths among patients who entered into HIV care late
occurred among those who presented with a more severe clinical
and immunological profile, had an initial CD4
+ T cell count
#100 cells/mm
3, or died within the first 20 days. In the population
of HIV-infected adults, 95.5% of the risk of death in the first 12
months was attributable to late entry into HIV care, meaning that
17,189 of the deaths occurring between 2003 and 2006 could have
been avoided had the patients entered into HIV care while still in
the early stages of HIV infection (Table 3). Among HIV-infected
adults (aged 15 years or older) in Brazil, the estimated number of
avoidable deaths corresponded to 39.5% of the total number of
deaths (43,523) recorded between 2003 and 2006 (Table 3).
Avoidable Death and Late Entry
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excluding the estimated number of avoidable deaths. We found
that the hypothetical reduction ranged from 43.3% (in 2003) to
34.1% (in 2006), the mean for the period as a whole being 39.5%.
In 2003 alone, that would have translated to a decrease in the
number of deaths per 100,000 population ($15 years of age) from
8.9 to 5.0 (Figure 4). Over the course of the study period, the
hypothetical number of avoidable deaths trended toward a
progressive decrease. In the last year of analysis (2006), the
percentage of the risk of death that was attributable to late entry
into HIV care was 96.4%, and the estimated number of deaths
that could have been avoided had the patients gained timely access
Table 1. Clinical and immunological status of HIV-infected adults ($15 years of age) upon entry into HIV care at public health care
facilities in Brazil.
2003 2004 2005 2006 2003–2006
Clinical and immunological status N % N % N % N % N %
Timely 13,093 53.5 15,971 56.5 18,043 56.5 17,904 58.4 65,011 56.4
Late 11,394 46.5 12,311 43.5 13,898 43.5 12,755 41.6 50,358 43.6**
CD4
+ T cell count and AIDS-defining illnesses
Timely .350 cells/mm
3 9,511 38.8 11,798 41.7 13,354 41.8 13,091 42.7 47,754 41.4
.200 and #350 cells/mm
3
without any AIDS-defining illness
3,582 14.6 4,173 14.8 4,689 14.7 4,813 15.7 17,257 15.0
Late .200 cells/mm
3 with
AIDS-defining illness
777 3.2 938 3.3 919 2.9 665 2.2 3,299 2.9
.100 and #200 cells/mm
3 2,717 11.1 3,134 11.1 3,563 11.2 3,557 11.6 12,971 11.2
#100 cells/mm
3 3,740 15.3 4,507 15.9 5,961 18.7 5,423 17.7 19,631 17.0
Death soon after entry into
HIV care*
4,160 17.0 3,732 13.2 3,455 10.8 3,110 10.1 14,457 12.5
Total 24,487 100 28,282 100 31,941 100 30,659 100 115,369 100
*within the first 20 days after entry.
**p,0.001 for the temporal trend of the prevalence of late entry (chi-square test).
doi:10.1371/journal.pone.0014585.t001
Figure 2. Probability of death from AIDS in the first 12 months after entry into HIV care.
doi:10.1371/journal.pone.0014585.g002
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avoidable deaths in 2003. This reduction was associated with the
annual decrease in late entry into HIV care and, consequently,
with the risk of death in the first 12 months, which fell from 20.3%
in 2003 to 12.5% in 2006 (Table 3). The mean proportion by
which the mortality rate would have been reduced had all patients
gained timely access to HIV care between 2003 and 2006 was
found to be similar to the 43.0% observed between 1995, the year
that preceded the introduction of antiretroviral therapy in Brazil,
and 2006 (Figure 5). If, during that same period (1995–2006), all
patients had also gained timely access to HIV care, the reduction
in mortality would have been 62.5%, increasing the effectiveness
of the HIV care program by 45.2%.
Late entry into HIV care including asymptomatic
individuals with CD4
+ T cell counts .200 and #350
cells/mm
3
The prevalence of late entry into HIV care between 2003 and
2006 increased to 58.6% when the asymptomatic individuals who
presented to public health care facilities with CD4
+ T cell counts
.200 and #350 cells/mm
3 (17,257; 15.0%) were included
(Table 4).
By applying the new criterion, the total number of deaths
among individuals who entered HIV care late increased to 17,793
(98.8% of the total of deaths among the individuals included in the
present study). The temporal distribution of the 249 deaths that
occurred among asymptomatic individuals with CD4
+ T cell
counts .200 and #350 cells/mm
3 was relatively homogeneous
(58.2% of the deaths having occurred by the end of the sixth
month). The mean CD4
+ T cell count was 265.5 cells/mm
3
(median, 260 cells/mm
3; range, 203–350 cells/mm
3) for the
asymptomatic individuals who died, compared with 277.1 cells/
mm
3 (median, 270 cells/mm
3; range, 201–350 cells/mm
3) for
those who did not.
Although the total number of deaths increased, the probability
of death from AIDS in the first 12 months of HIV care, according
to the new criterion, decreased to 27.6% (95% CI: 27.2–27.9) for
individuals who entered HIV care late and to 0.6% (95% CI: 0.5–
0.7) for those who gained timely access to HIV care. This was due
to the fact that the probability of death from AIDS in the first 12
Figure 3. Probability of death from AIDS in 12 months, according the timing of entry into care.
doi:10.1371/journal.pone.0014585.g003
Table 2. Probability of death from AIDS in the first 12 months due to late entry into HIV care.
Period (months) Late Entry (95% CI) Timely Entry (95% CI) Risk Ratio (95% CI)
#3 32.1 (31.7–32.5) 0.2 (0.2–0.3) - -
#6 34.4 (34.0–34.9) 0.5 (0.4–0.5) - -
#12 36.3 (35.9–36.7) 1.0 (0.9–1.1) 49.5 (45.1–54.2)
CI: confidence interval.
doi:10.1371/journal.pone.0014585.t002
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+ T cell counts
.200 and #350 cells/mm
3 (1.9%; 95% CI: 1.7–2.2) was lower
than was that for individuals previously classified as having entered
HIV care late (RR=0.04; 95% CI: 0.04–0.05). The RR for
asymptomatic individuals with CD4
+ T cell counts .200 and
#350 cells/mm
3, compared with those who gained timely access
to HIV care (CD4
+ T cell counts .350 cells/mm
3) was 3.3 (95%
CI: 2.7–3.9).
By applying the new criterion, the percentage of the risk of
death in the first 12 months attributable to late entry into HIV
care increased to 97.2%. This percentage corresponded to 17,497
deaths that were potentially avoidable had these individuals gained
timely access to HIV care (Table 4). In addition, the percentage of
avoidable deaths was 1.8% (308 deaths) higher than that observed
when the former criterion was applied. As can be seen in Table 4,
the mean reduction in the mortality rate increased from 39.5%
(CD4
+ T cell count #200 cells/mm
3 criterion) to 40.2% (CD4
+ T
cell count #350 cells/mm
3 criterion). Therefore, the mortality
rates for the 2003–2006 period remained practically the same.
Discussion
The results of the present study reveal that the risk of death
from AIDS in the first 12 months was fundamentally linked to late
entry into HIV care. The high proportion of individuals who
entered HIV care late increased AIDS mortality rates in Brazil by
more than one third. We also found that the effectiveness of the
Brazilian health care program for HIV-infected individuals—
considering the AIDS mortality rate as an indicator—could have
increased by nearly 50% had all such individuals gained timely
access to HIV care. Therefore, from a public health perspective,
universal timely access to HIV care would, proportionally, have
had the same impact that highly active antiretroviral drugs had
when they were first introduced in the country.
The impact of late entry into HIV care on the mortality rates in
Brazil was increased by the high proportion of individuals who
presented at health care facilities with advanced AIDS. Approx-
imately one third of those individuals presented with initial CD4
+
T cell counts #100 cells/mm
3 or died within the first 20 days and
therefore did not benefit from the available treatments.
The relationship between late entry into HIV care and an
increased risk of death (due to lower initial CD4
+ T cell counts and
a higher prevalence of AIDS-defining illnesses) has been
consistently reported in various studies [6–10,39]. However, in
such studies, the risk of death in the first year—11% in Thailand
[7], 10% in China [8], 8.4% in South Africa [9], 8.3% in Latin
American countries [10], and 6.4% in low-income countries
[39]—was lower than that observed in the present study. This
might be attributable to the differences among the study
populations (the aforementioned studies analyzed only individuals
Table 3. Risk (%) of death and percentage of the risk of death in the first 12 months attributable to late entry into HIV care in the
population of HIV-infected adults ($15 years of age).
Period
Deaths in the
first 12 months
Risk
Population
Risk Late
entry
Risk Timely
entry
Percentage of risk
attributable to late
entry
Avoidable
deaths
Total of deaths
among HIV+
adults
Reduction in
the total of
deaths (%)
2003 4,965 20.3 42.7 0.8 96.2 4,778 11,022 43.3
2004 4,678 16.5 37.0 0.8 95.5 4,465 10,790 41.4
2005 4,523 14.2 31.4 0.9 93.8 4,243 10,872 39.0
2006 3,836 12.5 29.4 0.4 96.4 3,699 10,839 34.1
2003–2006 18,002 15.6 34.8 0.7 95.5 17,189 43,523 39.5
doi:10.1371/journal.pone.0014585.t003
Figure 4. AIDS mortality rates and AIDS mortality rates adjusted by excluding avoidable deaths.
doi:10.1371/journal.pone.0014585.g004
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that patients who died soon after their entry into HIV care had on
the mortality rates observed in the present study. It should be
borne in mind that many of these patients did not receive
antiretroviral therapy or received it when the probability of
reconstitution of the immune response was more limited, thereby
contributing to the greater risk of death. When we excluded these
patients from our analysis, the risk of death in the first 12 months
decreased from 16.5% (95% CI: 16.3–16.7) to 4.6% (95% CI: 4.4–
4.7), a proportion that is closer to the 1.7% and 3.7% found in
cohort studies of patients under antiretroviral treatment in the
Brazilian cities of Sa ˜o Paulo [40] and Rio de Janeiro [10],
respectively, as well as to the 1.8% and 6.4% found in high-income
and low-income countries, respectively [39].
In general, the prevalence of late entry into HIV care in Brazil is
similar to the highest rates seen in high-income countries.
However, it is difficult to compare these findings due to the
difference among the various studies in terms of the parameters
used, which are based on different definitions of late entry. A study
conducted in Barcelona showed that, between 1987 and 2006,
43.9% of patients had been tested for HIV three months before
being diagnosed with AIDS [22]. A study conducted in 2005 in the
USA investigated 34,424 patients and reported that 36.4% of the
patients developed AIDS within the first year after being
diagnosed with HIV infection [23]. In a representative sample of
HIV-infected individuals diagnosed between 1996 and 2003 in
France [20], 33.1% of the patients presented to health care
facilities with AIDS-defining clinical events or CD4
+ T cell counts
,200 cells/mm
3. In medium-income and low-income countries,
studies of this type are scarce; however, in 17 different patient
cohorts in, variously, Africa, Asia, and South America, antiretro-
viral treatment was started in the presence of CD4
+ T cell counts
,200 cells/mm
3 in 77%, 78%, and 51% of the patients,
respectively [24]. Between 2004 and 2005, 55% of individuals in
southern Thailand presented with AIDS-related symptoms upon
entry into HIV care [25].
In Brazil, two studies investigating the clientele of referral
outpatient clinics, in the states of Sa ˜o Paulo and Minas Gerais,
respectively, showed that a high proportion of patients entered
into HIV care late. The study conducted in the state of Sa ˜o Paulo,
involving 1,229 patients and carried out between 1998 and 2002,
reported that 55% of the men and 38% of the women had
presented with a diagnosis of AIDS [41]. In the study conducted in
the state of Minas Gerais, late entry into HIV care was defined as
presenting with a CD4
+ T cell count ,200 cells/mm
3 or AIDS-
defining clinical events, and the proportion of patients who
received delayed antiretroviral therapy was 68.4% [26]. Another
study analyzed 84,694 HIV-infected patients treated at health care
facilities in Brazil and reported that 41% of such patients received
delayed antiretroviral treatment, the criterion adopted for the
Figure 5. Evolution of AIDS mortality rates adjusted by excluding avoidable deaths.
doi:10.1371/journal.pone.0014585.g005
Table 4. Comparison between two late entry criteria—inclusion and non-inclusion of asymptomatic individuals with CD4
+ T cell
counts #350/mm
3—in terms of their impact on AIDS mortality rates, 2003–2006.
Indicator
Asymptomatic individuals with CD4
+ T
cell counts #350 cells/mm
3 included
Asymptomatic individuals with CD4
+ T
cell counts #350 cells/mm
3 not included
Probability of death within the first 12 months (timely entry) 0.4 1.0
Probability of death within the first 12 months (late entry) 26.3 36.3
Risk of death attributable to late entry 97.2 94.0
Avoidable deaths 17,497 16,963
Reduction in the total number of deaths (%) 40.2 38.9
Adjusted mortality rates (2006) 5.39 5.44
doi:10.1371/journal.pone.0014585.t004
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+ T
cell count ,200 cells/mm
3 or symptoms of AIDS [27].
In the present study, the inclusion of asymptomatic individuals
with CD4
+ T cell counts .200 and #350 cells/mm
3 increased the
prevalence of late entry into HIV care by approximately 35%.
However, this resulted in a less than 2% increase in the
proportional reduction in the AIDS mortality rates due to the
promotion of timely entry into HIV care. This minimal increase
resulted from the low risk of death in the first 12 months (1.9%)
observed among asymptomatic individuals with CD4
+ T cell
counts .200 and # and 350 cells/mm
3 and, in part, from the
Brazilian guidelines, which, since the early 2000s, have recom-
mended that, in specific clinical and immunological situations,
antiretroviral therapy be started in patients with CD4
+ T cell
counts #350 cells/mm
3 [42]. Of the asymptomatic patients with
CD4
+ T cell counts .200 and #350 cells/mm
3 included in the
present study, 68% used antiretroviral drugs during the study
period. Among those patients, the proportional mortality in the
first 12 months was approximately 4 times lower than was that
observed for individuals who did not receive antiretroviral therapy
(0.7% vs. 3.0%).
It should be highlighted that, even if we considered a scenario in
which none of the asymptomatic patients with CD4
+ T cell counts
#350 cells/mm
3 had received antiretroviral therapy during the
study period and therefore assumed that the proportional
mortality for the entire group was the same as that observed for
patients who did not receive antiretroviral therapy, the impact of
such patients on the increase in the number of avoidable deaths
and, consequently, on the reduction in the mortality rates would
not have been significantly greater than was that observed by
adopting a CD4
+ T cell count #200 cells/mm
3 and being a
symptomatic patient as late entry criteria. In that case, another
569 deaths (3.3%) would have been averted, and the proportional
reduction in mortality would have increased from 39.5% to
40.8%.
The abovementioned findings bring some new elements to the
discussion about the potential benefits of the WHO recommen-
dation on AIDS mortality [28]. The studies on which the WHO
based its decision used relative risks as measures of the association
between early treatment and mortality. Those studies showed that
the risk of death and of progression of the infection in patients who
received early antiretroviral therapy was only 25% of that
observed in patients who did not receive the drugs in a timely
manner [28,43–45]. However, the findings of the present study
suggest that, from a population perspective, such benefits are not
as significant, since deaths among asymptomatic patients with
CD4
+ T cell counts #350 cells/mm
3 are uncommon, regardless of
whether they were receiving antiretroviral therapy at the time.
This might motivate researchers to conduct other studies, with the
objective of establishing clinical and immunological parameters
that are more accurate in identifying patients that will indeed
benefit from antiretroviral therapy upon entry into HIV care (thus
avoiding the excessive use of drugs), as well as of providing the
basis for a definition of priorities for the use of antiretroviral
therapy in a context of limited resources, prioritizing individuals at
higher risk of impaired health status.
The reduction in the prevalence of late entry into HIV care in
Brazil between 2003 and 2006, albeit slight, was an encouraging
finding, which might be attributable to the adoption of public
policies to promote early diagnosis of the infection. Studies
examining the organization of health care facilities and the
Brazilian response to AIDS have shown that, beginning in 2003
(when a national program encouraging individuals to be tested for
HIV was launched), the number of voluntary counseling and
testing centers increased [46], as did the number of diagnoses
made via the public health system [29]. In addition, population-
based studies in Brazil [15] have shown that the proportion of
adult individuals tested for HIV increased (by 66.3%) between
1998 and 2005.
The findings of the present study should be examined in light of
its limitations, which are primarily related to the data sources used.
The principal limitation is related to the possibility that, due to
underreporting and problems inherent to routine databases, the
information systems failed to include a proportion of HIV-infected
individuals in the country. This might have been caused by data
entry omissions systems, by the unavailability of CD4
+ T cell
counting at the public health care facilities upon entry into HIV
care, or by the fact that a proportion of patients undergo CD4
+ T
cell counting at private laboratories, meaning that some
information regarding those individuals was not included in the
SISCEL. In an attempt to minimize the limitations resulting from
underreporting, we cross-referenced the information systems,
which allowed us to retrieve a variety of information that
documented entry into HIV care at public health care facilities.
In addition, we chose not to analyze data collected prior to 2003.
This decision was based on the fact that the coverage rates of the
information systems, especially those of the SISCEL, increased
significantly as of 2003. Therefore, as mentioned in the Methods
section, the coverage rates of the information systems used in the
present study are absolutely acceptable. In addition, the public
laboratory network for CD4
+ T cell counting has extensive
coverage in Brazil, having been responsible for a mean annual
number of tests, between 2003 and 2006, of 298,600 (range
257,400–325,700), translating to 1.8 tests per patient being
followed via public health care facilities (median, 1.8; interquartile
range: 1.3–2.1) in 2006. Even in the northern region of Brazil,
which is the least economically developed region of the country
and in which access to health care facilities is the most limited, this
number was 1.5 (median, 1.5).
In order to determine the possible effect of underreporting, we
analyzed the characteristics of 18,638 patients who had not
undergone CD4
+ T cell counting by the sixth month of follow-up.
These patients were similar to the total of patients analyzed in
terms of gender and age, and the proportional mortality in the first
12 months was closer to that observed in individuals who gained
timely access to HIV care (1.2%). Therefore, if we had included
these 18,638 individuals in the group of patients who gained timely
access to HIV care, the proportional mortality in the first 12
months would have been 12.9%, and the risk of death attributable
to late entry would have been 91.9%. This would have meant that
the number of avoidable deaths had been overestimated by 2.5%.
The possibility that data related to individuals at greater risk of
late entry into HIV care were not included in the databases
represents a potential limitation and should be taken into
consideration because it might have led to an underestimation of
the number of avoidable deaths and of the extrapolated rate of
reduction in mortality. However, the available data suggest that
this is unlikely to have occurred. Studies that have analyzed
underreporting in the databases of Brazil have focused on the
reporting of AIDS cases, the risk of underreporting being highest
for women, for individuals with a low level of education, and for
patients treated at private health care facilities [47], women
reportedly representing the group with the lowest risk of late entry
into HIV care [27,41]. There are no consistent data regarding
individuals with a low level of education. Taking into consider-
ation social aspects, the study conducted in the state of Minas
Gerais [26] showed that there was an association between delayed
antiretroviral therapy initiation and unemployment. Patients being
Avoidable Death and Late Entry
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proportion of the cases of HIV infection and AIDS in Brazil and
therefore were not included in the present study.
It is of note that the reduction in the prevalence of late entry
into HIV care and of avoidable deaths observed in the present
study might be associated with a delay in the reporting of deaths
among HIV-infected individuals, especially among those who
require further investigation because the diagnosis of AIDS was
not listed as the underlying cause of death on the death certificate.
This delay is more likely to have occurred in the last year of
analysis (2006). However, we believe that it is unlikely that such a
delay was sufficiently long as to alter the systematic trend toward a
reduction observed in all of the studies analyzed. This might have
occurred if there had been a delay in the reporting of 38.7% of the
deaths that occurred in 2006. In addition, it should be borne in
mind that the proportional losses to follow-up are unlikely to have
significantly influenced the number of deaths observed in the
period, since those data were obtained from the SIM.
Despite the limitations described here, it should be borne in
mind that Brazil has a broad national health care program for
HIV-infected individuals (a program that has provided universal
access to antiretroviral drugs since 1991), as well as information
systems that allowed the monitoring of more than 130,000 patients
who entered into HIV care at public health care facilities between
2003 and 2006. These aspects provide the basis for the population
estimates made in the present study, and our findings allow us to
suggest that addressing the issue of late entry into HIV care will
have, at this juncture, in Brazil and in other countries, an impact
similar to that of the introduction of highly active antiretroviral
therapy.
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